Shanghai Caerulum Pharma Discovery
Business Type:Manufacturer
Country/Region:China
Ddu Verified
HOT Rank
Shanghai Caerulum Pharma Discovery
We are professional supplier of api.
Shanghai Caerulum Pharma Discovery
We are professional supplier of api.
Business Type:Manufacturer
Country/Region:China
Ddu Verified
HOT Rank
Quizartinib, also know as AC220 and AC010220, is an orally available FLT3 / STK1 inhibitor with potential antineoplastic activity. Class III receptor tyrosine kinase inhibitor AC220 selectively inhibits class III receptor tyrosine kinases, including FMS-related tyrosine kinase 3 (FLT3/STK1), colony-stimulating factor 1 receptor (CSF1R/FMS), stem cell factor receptor (SCFR/KIT), and platelet derived growth factor receptors (PDGFRs), resulting in inhibition of ligand-independent leukemic cell proliferation and apoptosis. Mutations in FLT3, resulting in constitutive activation, are the most frequent genetic alterations in acute myeloid leukemia (AML) and occur in approximately one-third of AML cases.
Shanghai Caerulum Pharma Discovery is the manufacturer of APIs and intermediates of some of the latest compounds in the market. Our focus is on cancer, diabetes and other therapeutic areas.
Shanghai Caerulum Pharma Discovery (CPD) offers high quality and reliable chemical products and integrated biological services including:
1) Best offer for existing APIs and intermediates
2) Custom-synthesis APIs and intermediates
3) DMPK
4) Biological screening
5) Drug Safety Evaluation
